American heart journal最新文献

{"title":"Corrigendum to “Long-term safety and outcomes after atrial shunting for heart failure with preserved or mildly reduced ejection fraction: 5-year and 3-year follow-up in the REDUCE LAP-HF I and II trials” [American Heart Journal (278)2024 Page Number:106-116]","authors":"Sheldon E Litwin , Jan Komtebedde , Barry A Borlaug , David M Kaye , Gerd Hasenfuβ , Rami Kahwash , Elke Hoendermis , Scott L Hummel , Maja Cikes , Finn Gustafsson , Eugene S Chung , Rajeev C Mohan , Aaron L Sverdlov , Vijendra Swarup , Sebastian Winkler , Christopher S Hayward , Martin W Bergmann , Heiko Bugger , Scott McKenzie , Ajith Nair , Sanjiv J Shah","doi":"10.1016/j.ahj.2025.107312","DOIUrl":"10.1016/j.ahj.2025.107312","url":null,"abstract":"","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":"293 ","pages":"Article 107312"},"PeriodicalIF":3.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145787181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of supersaturated oxygen therapy on infarct size and microvascular obstruction following myocardial infarction: A systematic review and meta-analysis","authors":"Shanmukh Sai Pavan Lingamsetty MD ,&nbsp;Ravi Venkata Sai Krishna Medarametla MD ,&nbsp;Kesar Prajapati MD ,&nbsp;Sahas Reddy Jitta MD ,&nbsp;Mohamed Doma MD ,&nbsp;Harshith Thyagaturu MD ,&nbsp;Mangesh Kritya MD ,&nbsp;Jaswanth Jasti MD ,&nbsp;Mohan Chandra Vinay Bharadwaj Gudiwada MD ,&nbsp;Chenna Reddy Tera MD ,&nbsp;Tirumala Nischal Jasty MD ,&nbsp;Pradeep Kumar Devarakonda MD ,&nbsp;Vikramaditya Reddy Samala Venkata MD ,&nbsp;Mir B Basir DO ,&nbsp;Michael S Megaly MD, MSc ,&nbsp;Amir Lotfi MD ,&nbsp;Andrew M Goldsweig MD, MS","doi":"10.1016/j.ahj.2025.107311","DOIUrl":"10.1016/j.ahj.2025.107311","url":null,"abstract":"<div><h3>Background</h3><div>Supersaturated oxygen (SSO₂) therapy is an emerging intervention to minimize myocardial damage and improve outcomes in patients with ST-segment elevation myocardial infarction (STEMI). This meta-analysis evaluated the efficacy of SSO₂ therapy to reduce infarct size and microvascular obstruction (MVO).</div></div><div><h3>Methods</h3><div>PubMed, Embase, and Cochrane databases were systematically searched for studies comparing percutaneous coronary intervention (PCI) plus SSO₂ to PCI alone for STEMI. Outcomes of interest included infarct size, MVO, and subsequent major adverse cardiovascular events (MACE), all-cause mortality, re-infarction, and target vessel revascularization (TVR). Mean differences (MD) with 95% confidence intervals (CIs) were calculated using random-effects models.</div></div><div><h3>Results</h3><div>Six studies (<em>n</em> = 1660) were included with 548 patients (33%) receiving SSO₂ therapy. Pooled analysis showed that PCI plus SSO₂ significantly reduced infarct size (MD −4.31; 95% CI −6.70 to −1.92; <em>P</em> &lt; .01) and MVO (SMD −0.72; 95% CI −1.11 to −0.34; <em>P</em> &lt; .01) compared with PCI alone. MACE, all-cause mortality, re-infarction, and TVR were comparable between the groups.</div></div><div><h3>Conclusion</h3><div>SSO₂ therapy significantly reduced infarct size and MVO in patients undergoing PCI for STEMI.</div></div>","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":"293 ","pages":"Article 107311"},"PeriodicalIF":3.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145627652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond cumulative exposure: The roles of glycemic variability and metabolic memory in cardiac dysfunction","authors":"Mohammed Ahmed Taha Aly ElDabour (محمد أحمد طه علي الدبور) ,&nbsp;Israa Yasser Salah Ahmed (إسراء ياسر صلاح احمد)","doi":"10.1016/j.ahj.2025.107305","DOIUrl":"10.1016/j.ahj.2025.107305","url":null,"abstract":"","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":"293 ","pages":"Article 107305"},"PeriodicalIF":3.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145534154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to letter to the editor, titled: Beyond cumulative exposure: The roles of glycemic variability and metabolic memory in cardiac dysfunction","authors":"Yilin Yoshida PhD, MPH, FAHA","doi":"10.1016/j.ahj.2025.107306","DOIUrl":"10.1016/j.ahj.2025.107306","url":null,"abstract":"","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":"293 ","pages":"Article 107306"},"PeriodicalIF":3.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145534141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Routine versus selective protamine administration to reduce bleeding after TAVI: Rationale and design of the POPular ACE TAVI trial","authors":"Daniël C. Overduin MD ,&nbsp;Dirk Jan van Ginkel MD ,&nbsp;Christophe Dubois MD, PhD ,&nbsp;Pierluigi Lesizza MD ,&nbsp;Gijs M. Broeze MSc ,&nbsp;Jose M. Montero-Cabezas MD, PhD ,&nbsp;Liesbeth Rosseel MD, PhD ,&nbsp;Frank van der Kley MD, PhD ,&nbsp;Puck JA van Nuland MD ,&nbsp;Thijs PM Smits MD ,&nbsp;Kimberley I. Hemelrijk MD ,&nbsp;Hugo M. Aarts MD ,&nbsp;Benno J.W.M. Rensing MD, PhD ,&nbsp;Leo Timmers MD, PhD ,&nbsp;Martin J. Swaans MD, PhD ,&nbsp;Uday Sonker MD ,&nbsp;Leo Veenstra MD ,&nbsp;Arnoud W.J. van 't Hof MD, PhD ,&nbsp;Joyce Peper PhD ,&nbsp;Jan G.P. Tijssen PhD ,&nbsp;Jurriën M. ten Berg MD, PhD","doi":"10.1016/j.ahj.2025.107296","DOIUrl":"10.1016/j.ahj.2025.107296","url":null,"abstract":"<div><h3>Background</h3><div>Unfractionated heparin is routinely used during transcatheter aortic valve implantation (TAVI) to reduce catheter thrombosis and thromboembolism. Protamine reverses the effect of heparin and may lower bleeding risk, but it can also trigger severe allergic reactions. Robust data on the safety and efficacy of routine protamine administration after TAVI is lacking.</div></div><div><h3>Methods</h3><div>The ``routine versus selective protamine administration to reduce bleeding complications after transcatheter aortic valve implantation (POPular ACE TAVI)'' is an investigator-initiated, multicenter, double-blind, placebo-controlled, randomized clinical trial. A total of 1000 patients will be randomized 1:1 to routine versus selective protamine administration, stratified by study site and antithrombotic therapy. Primary and secondary outcomes are defined according to the Valve Academic Research Consortium-3 (VARC-3) criteria. The primary outcome is a composite of all-cause mortality and clinically relevant bleeding (type 1-4) within 30 days after TAVI. Ranked secondary outcomes include clinically relevant bleeding; major, life-threatening or fatal bleeding (type 2-4); major vascular complications; cardiovascular mortality; and all-cause mortality. Safety outcomes include anaphylaxis and thromboembolic events defined as the composite of myocardial infarction, ischemic stroke, transient ischemic attack, or noncerebral distal embolization. Recruitment began in November 2023 and will continue until 1,000 patients are randomized. The trial will end after 30‑day follow‑up of the last patient.</div></div><div><h3>Conclusion</h3><div>The POPular ACE TAVI trial (NCT05774691) will evaluate whether routine protamine administration reduces all-cause mortality or clinically relevant bleeding after TAVI compared with selective use.</div></div><div><h3>Trial registration</h3><div><span><span>clinicaltrials.gov</span><svg><path></path></svg></span>. Unique identifier NCT05774691.</div></div>","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":"293 ","pages":"Article 107296"},"PeriodicalIF":3.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145429951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differences in guideline directed medical therapy for rural and non-rural Veterans with heart failure with reduced ejection fraction","authors":"Alexandra B. Steverson MD, MPH ,&nbsp;Jun Fan MS ,&nbsp;Natasha Din MBBS, MAS ,&nbsp;Neil Kalwani MD, MPP ,&nbsp;Anubodh S. Varshney MD ,&nbsp;Aradhana Verma MD ,&nbsp;Hayden B. Bosworth PhD ,&nbsp;Tomasz Jurga PharmD ,&nbsp;Paul L. Hess MD, MHS ,&nbsp;Paul Heidenreich MD, MS ,&nbsp;Alexander Sandhu MD, MS","doi":"10.1016/j.ahj.2025.107300","DOIUrl":"10.1016/j.ahj.2025.107300","url":null,"abstract":"<div><h3>Background</h3><div>There is a high burden of hospitalizations and deaths annually due to heart failure (HF) in the United States despite effective medical therapy and rural areas may be disproportionately affected. We sought to compare guideline-directed medical therapy (GDMT) utilization between rural and non-rural Veterans with HF with reduced ejection fraction (HFrEF).</div></div><div><h3>Methods</h3><div>We performed a cross sectional cohort study of Veterans with HFrEF (LVEF ≤ 40%) on January 1, 2022. The VA is an integrated health system with reduced financial barriers, which has a high proportion of rural patients. We compared the frequency of medication fills among rural and non-rural Veterans for renin-angiotensin system inhibitors (RASi), beta-blockers (BB), mineralocorticoid receptor antagonists (MRA) and sodium glucose co-transporter 2 inhibitors (SGLT2i). We used a continuous version of the 4-pillar score (C4P) to assess medical therapy intensity. We used multivariable logistic regression to identify patient characteristics associated with a high C4P score.</div></div><div><h3>Results</h3><div>Of 65,025 Veterans with HFrEF, 23,728 (36.5%) resided in a rural location, defined as RUCA (Rural–Urban Commuting Areas) code of greater than 1.1. Compared with non-rural, rural Veterans were more frequently White (82.5% vs 63.9%, <em>P</em> &lt; .01) and had a higher burden of comorbidities. Rural Veterans had longer drive times to primary (32 vs 15 minutes, <em>P</em> &lt; .01) and specialty (74 vs 36 minutes, <em>P</em> &lt; .01) care and were less likely to receive VA Cardiology care (44.4% vs 55.8%, <em>P</em> &lt; .01) or care at a high-complexity (level 1a) VA facility (36.4% vs 50.4%, <em>P</em> &lt; .01). Rural Veterans were less frequently prescribed &gt;50% target dose of RASi (19.9% vs 20.2%, <em>P</em> &lt; .01) and BBs (30.9% vs 32.2%, <em>P</em> &lt; .03) and less frequently prescribed SGLT2i (16.3% vs 18.9%, <em>P</em> &lt; .01) and MRA (27.8% vs 28.6%, <em>P</em> &lt; .03) therapy. Rural Veterans were significantly less likely to have a C4P score in the highest decile (OR 0.94, CI: 0.90-0.99) compared with non-rural Veterans.</div></div><div><h3>Conclusion</h3><div>Rural Veterans with HFrEF were slightly less likely be prescribed comprehensive GDMT. This small difference may be related to gaps in access to VA cardiology and high-complexity facilities. Novel interventions and quality initiatives are needed to decrease disparities in HFrEF care for rural Veterans.</div></div>","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":"293 ","pages":"Article 107300"},"PeriodicalIF":3.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145429935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Towards an understanding of best practice: The good, the bad and the future of cardiogenic shock teams","authors":"Balimkiz Senman MD ,&nbsp;Shashank S. Sinha MD, MSc ,&nbsp;Alexander G. Truesdell MD ,&nbsp;Israel Safiriyu MD ,&nbsp;Stavros Drakos MD, PhD ,&nbsp;Allison G. Dupont MD ,&nbsp;Mir Babar Basir DO ,&nbsp;P. Elliott Miller MD, MHS ,&nbsp;Aniket S. Rali MD ,&nbsp;Courtney Bennett DO ,&nbsp;Behnam Tehrani MD ,&nbsp;Jennifer Cowger MD, MS ,&nbsp;Shelley A. Hall MD ,&nbsp;Carolyn Rosner RN, BSN, MSN, NP-C, MBA ,&nbsp;Amy E. Hackmann MD ,&nbsp;David E. Wang MD ,&nbsp;Alexander I. Papolos MD ,&nbsp;Bernard S. Kadosh MD ,&nbsp;Saraschandra Vallabhajosyula MD, MSc ,&nbsp;Michelle Ferri MS, ACNP-BC ,&nbsp;Jason N. Katz MD, MHS","doi":"10.1016/j.ahj.2025.107310","DOIUrl":"10.1016/j.ahj.2025.107310","url":null,"abstract":"<div><div>Cardiogenic shock (CS) remains a high-mortality condition that demands rapid diagnosis, coordinated multidisciplinary management, and timely initiation of mechanical circulatory support. As more institutions implement dedicated CS teams, substantial heterogeneity has emerged in how these teams are structured, activated, and sustained. To better characterize this variability and begin defining the components of an optimal CS team, the Society of Critical Care Cardiology (SoCCC), in partnership with the Society for Cardiovascular Angiography and Interventions (SCAI), convened the Inaugural Cardiogenic Shock Teams Think Tank. Held on October 17, 2024, as a preconference program to SCAI SHOCK 2024 in Washington, DC, the meeting brought together national leaders in CS care, mechanical circulatory support, and resuscitation to identify shared challenges and propose practical solutions.</div><div>This manuscript summarizes key insights from this inaugural Think Tank, which represents the first in an ongoing series of collaborative efforts aimed at informing the standardization and optimization of CS teams nationwide. Specifically, we review the ideal composition and core competencies of a CS team; the rationale and emerging evidence supporting dedicated team-based CS care; activation algorithms and operational workflows; and common barriers to establishing and sustaining such teams. We also outline future directions and opportunities to strengthen collaborative infrastructure, refine clinical pathways, and enhance the reliability, responsiveness, and effectiveness of cardiogenic shock teams across diverse healthcare settings.</div></div>","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":"293 ","pages":"Article 107310"},"PeriodicalIF":3.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145595698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re. response to “Occlusion vs subocclusion of the left main, the ECG pattern has the word”","authors":"Scott W. Sharkey MD ,&nbsp;Frank Aguirre MD ,&nbsp;Balaj Rai MD ,&nbsp;Timothy D Henry MD","doi":"10.1016/j.ahj.2025.107304","DOIUrl":"10.1016/j.ahj.2025.107304","url":null,"abstract":"","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":"293 ","pages":"Article 107304"},"PeriodicalIF":3.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145534112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rationale, design, and baseline characteristicss of the effect of PCSK9 inhibition on cardiovascular risk in treated HIV infection: EPIC-HIV randomized clinical trial.","authors":"Matthew S Durstenfeld, Marta Levkova-Clark, Danny Li, Veronica Schaffer, Shady Abohashem, Yifei Ma, Kosuke Kawai, Michael T Lu, Irini Sereti, Steven G Deeks, Ahmed Tawakol, Priscilla Y Hsue","doi":"10.1016/j.ahj.2026.107400","DOIUrl":"10.1016/j.ahj.2026.107400","url":null,"abstract":"<p><strong>Rationale: </strong>People with HIV (PWH) are at increased risk of cardiovascular disease. Moderate lipid lowering with statins has been demonstrated to reduce cardiovascular risk among PWH. Accordingly, evaluation of more potent lipid-lowering strategies for prevention is needed, especially for PWH at higher risk. Prior research suggests that proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors safely lower low-density lipoprotein cholesterol by 60% among people with HIV, but the impact of PCSK9 inhibitors on arterial inflammation, endothelial function, coronary plaque, or markers of immune dysfunction among PWH remains unknown.</p><p><strong>Methods: </strong>The effect of PCSK9 inhibition on cardiovascular risk in treated HIV infection study is a randomized, placebo-controlled, and double-blinded clinical trial. Adults at least 40 years old with treated and virally suppressed HIV and at least one cardiovascular risk factor (primary prevention) or a prior cardiovascular event (secondary prevention) are randomized in a 2:1 ratio to alirocumab or a matching placebo injected subcutaneously. ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography, coronary computed tomographic angiography, and flow-mediated dilation of the brachial artery are conducted at baseline and after 1 year of treatment. The primary study outcome is the change in arterial inflammation assessed using the target-to-background ratio of the most diseased arterial segment on positron emission tomography/computed tomography from baseline to 1 year, and key secondary endpoints will include the change in noncalcified coronary plaque on coronary computed tomographic angiography, change in endothelial function, and safety according to the intention-to-treat principle.</p><p><strong>Enrollment: </strong>One hundred eighteen participants were randomized. The mean age was 59.5 years, and 6% were female.</p><p><strong>Conclusions: </strong>The effect of PCSK9 inhibition on cardiovascular risk in treated HIV infection study will provide evidence regarding the mechanisms by which potent lipid lowering with PCSK9 inhibitors may alter the pathogenesis of atherosclerosis among PWH.</p><p><strong>Trial registration: </strong>https://clinicaltrials.gov/study/NCT03207945.</p>","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":" ","pages":"107400"},"PeriodicalIF":3.5,"publicationDate":"2026-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147343727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From hepatic congestion to ventricular stiffness: Mechanistic pathways of diastolic dysfunction after Fontan.","authors":"Ashish H Shah","doi":"10.1016/j.ahj.2026.107396","DOIUrl":"10.1016/j.ahj.2026.107396","url":null,"abstract":"","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":" ","pages":"107396"},"PeriodicalIF":3.5,"publicationDate":"2026-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147343682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}